📊 PBYI Key Takeaways
Is Puma Biotechnology, Inc.. (PBYI) a Good Investment?
PBYI demonstrates exceptional financial fundamentals with 16.3% operating margins, 23.9% ROE, and robust free cash flow generation of $41.7M (18.3% FCF margin), supported by a fortress balance sheet with minimal leverage (0.17x Debt/Equity). However, revenue stagnation (-0.9% YoY) and declining EPS (-1.6% YoY) raise sustainability concerns for a pharmaceutical company, requiring close monitoring of pipeline and market positioning.
Why Buy Puma Biotechnology, Inc.. Stock? PBYI Key Strengths
- Outstanding profitability with 16.3% operating margin and 13.6% net margin indicating efficient cost management
- Exceptional free cash flow generation (41.7M annually, 18.3% FCF margin) with minimal capital intensity (71K CapEx)
- Fortress balance sheet with 0.17x Debt/Equity ratio and 11.1x interest coverage providing financial flexibility
- Strong return metrics with 23.9% ROE and 14.4% ROA demonstrating efficient capital deployment
- Solid liquidity position with 2.00x current ratio and 1.93x quick ratio
PBYI Stock Risks: Puma Biotechnology, Inc.. Investment Risks
- Revenue decline of 0.9% YoY and declining diluted EPS of 1.6% YoY suggest potential market share losses or product maturity concerns
- Pharmaceutical sector inherently exposed to patent expirations, regulatory changes, and competitive pressures without disclosed pipeline information
- Minimal insider activity (only 3 Form 4 filings in 90 days) may indicate limited insider confidence in growth trajectory
- Missing gross margin disclosure limits analysis of pricing power and cost structure
- Stagnant revenues in a growth-dependent pharmaceutical sector raises long-term sustainability questions
Key Metrics to Watch
- Sequential revenue trends and year-over-year growth rate to confirm stabilization versus continued decline
- Operating cash flow maintenance and free cash flow conversion ratio to ensure cash generation durability
- R&D spending levels and pipeline advancement to assess future growth drivers
- Debt/Equity ratio and cash position to monitor financial flexibility
- Insider buying activity and Form 4 filings as sentiment indicators
Puma Biotechnology, Inc.. (PBYI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.00x current ratio provides a solid financial cushion.
PBYI Profit Margin, ROE & Profitability Analysis
PBYI vs Healthcare Sector: How Puma Biotechnology, Inc.. Compares
How Puma Biotechnology, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Puma Biotechnology, Inc.. Stock Overvalued? PBYI Valuation Analysis 2026
Based on fundamental analysis, Puma Biotechnology, Inc.. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Puma Biotechnology, Inc.. Balance Sheet: PBYI Debt, Cash & Liquidity
PBYI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Puma Biotechnology, Inc..'s revenue has declined by 13% over the 5-year period, indicating business contraction. The most recent EPS of $0.45 reflects profitable operations.
PBYI Revenue Growth, EPS Growth & YoY Performance
PBYI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $54.5M | $8.8M | $0.17 |
| Q2 2025 | $47.1M | -$4.5M | $-0.09 |
| Q1 2025 | $43.8M | $3.0M | $0.06 |
| Q3 2024 | $56.1M | $5.8M | $0.12 |
| Q2 2024 | $47.1M | $2.1M | $0.05 |
| Q1 2024 | $43.8M | $1.4M | $0.03 |
| Q3 2023 | $56.1M | -$360.0K | $-0.01 |
| Q2 2023 | $54.6M | $2.1M | $0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Puma Biotechnology, Inc.. Dividends, Buybacks & Capital Allocation
PBYI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Puma Biotechnology, Inc.. (CIK: 0001401667)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PBYI
What is the AI rating for PBYI?
Puma Biotechnology, Inc.. (PBYI) has an AI rating of BUY with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PBYI's key strengths?
Claude: Outstanding profitability with 16.3% operating margin and 13.6% net margin indicating efficient cost management. Exceptional free cash flow generation (41.7M annually, 18.3% FCF margin) with minimal capital intensity (71K CapEx).
What are the risks of investing in PBYI?
Claude: Revenue decline of 0.9% YoY and declining diluted EPS of 1.6% YoY suggest potential market share losses or product maturity concerns. Pharmaceutical sector inherently exposed to patent expirations, regulatory changes, and competitive pressures without disclosed pipeline information.
What is PBYI's revenue and growth?
Puma Biotechnology, Inc.. reported revenue of $228.4M.
Does PBYI pay dividends?
Puma Biotechnology, Inc.. does not currently pay dividends.
Where can I find PBYI SEC filings?
Official SEC filings for Puma Biotechnology, Inc.. (CIK: 0001401667) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PBYI's EPS?
Puma Biotechnology, Inc.. has a diluted EPS of $0.61.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PBYI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Puma Biotechnology, Inc.. has a BUY rating with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is PBYI stock overvalued or undervalued?
Valuation metrics for PBYI: ROE of 23.9% (sector avg: 15%), net margin of 13.6% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy PBYI stock in 2026?
Our dual AI analysis gives Puma Biotechnology, Inc.. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is PBYI's free cash flow?
Puma Biotechnology, Inc..'s operating cash flow is $41.8M, with capital expenditures of $71.0K. FCF margin is 18.3%.
How does PBYI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 13.6% (avg: 12%), ROE 23.9% (avg: 15%), current ratio 2.00 (avg: 2).